Ophthalmology. Retina最新文献

{"title":"Foveal Cavitations by High-resolution OCT after Acute Macular Neuroretinopathy","authors":"Lorenzo Ferro Desideri MD , Martin Zinkernagel MD, PhD , Rodrigo Anguita MD","doi":"10.1016/j.oret.2024.12.022","DOIUrl":"10.1016/j.oret.2024.12.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Page e82"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-arterial Chemotherapy for Retinoblastoma, Outcomes Analysis in 357 Eyes","authors":"Luiz F. Teixeira MD ,&nbsp;Carla R.P.D. Macedo MD ,&nbsp;José R.F. Fonseca MD, PhD ,&nbsp;Bruna Morales RN ,&nbsp;Monique K. Mangeon MD ,&nbsp;Bruno A. Miranda MD ,&nbsp;Ricardo Casaroli-Marano MD, PhD ,&nbsp;Juliana M.F. Sallum MD, PhD","doi":"10.1016/j.oret.2025.02.013","DOIUrl":"10.1016/j.oret.2025.02.013","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the outcomes of intra-arterial chemotherapy (IAC) for the treatment of naive and nonnaive retinoblastoma eyes. Ocular survival rates, risk factors for enucleation, ocular complications, metastatic disease, and overall survival were analyzed.</div></div><div><h3>Design</h3><div>A retrospective, single-institution study.</div></div><div><h3>Participants</h3><div>A total of 300 patients treated with IAC between April 2010 and April 2023 were included.</div></div><div><h3>Interventions</h3><div>During IAC infusions, 1 to 3 drugs were used (melphalan, 3.0–7.5 mg; topotecan, 0.3–2.0 mg; and carboplatin, 20–50 mg). Adjuvant therapy was used as needed to consolidate treatment.</div></div><div><h3>Main Outcome Measures</h3><div>Ocular survival rates, ocular complications, and the risk factors for enucleation were measured.</div></div><div><h3>Results</h3><div>A total of 357 eyes were treated with 1536 IAC infusions, with a median of 4 cycles per eye, and followed for 60.69 months. The Kaplan–Meier estimates for the overall ocular survival were 90% at 1 year, 89% at 2 years, and 86% at 5 years. No difference in ocular survival was found between IAC indications (primary 88% vs. secondary 85% vs. bridge 89%; <em>P</em> = 0.52) and the use of tandem therapy (tandem 85% vs. no tandem 87%; <em>P</em> = 0.93). Intravitreal chemotherapy was used as adjuvant therapy in 31.37% and plaque therapy in 5% of the eyes. The group did not receive external beam radiation. Univariable and multivariable analyses showed that the presence of subretinal seeds was significantly associated with an increased risk of enucleation, and the use of ophthalmic artery (OA) ostium in &gt;50% of infusions per eye was a protective factor to avoid enucleation. Retinal and choroidal vascular, ischemic, or atrophic effects were the most frequent complications found in 5.0% of the eyes. Metastatic disease was observed in 0.33% of the patients. The overall 5-year patient survival was 99.3%.</div></div><div><h3>Conclusions</h3><div>The use of IAC in different indications (primary, secondary, bridge, and tandem) to treat naive or recurrent–refractory retinoblastomas showed successful results. Most eyes were preserved. Subretinal seeds at presentation were associated with a high enucleation risk. The use of the OA ostium for drug delivery avoided enucleation.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 798-806"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Retrobulbar Spot Sign in Central Retinal Artery Occlusion","authors":"Fernando Pellerano MD,&nbsp;Joseph D. Bogaard MD, PhD","doi":"10.1016/j.oret.2024.12.011","DOIUrl":"10.1016/j.oret.2024.12.011","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Page e79"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to Hydroxychloroquine Dosing Guidelines at the University of California","authors":"Kareem Moussa MD ,&nbsp;Jaipreet S. Virk BS ,&nbsp;Brian Paciotti PhD, MS ,&nbsp;Blythe P. Durbin-Johnson PhD ,&nbsp;Jessica G. Shantha MD, Msc ,&nbsp;Edmund Tsui MD, MS ,&nbsp;Catherine Q. Sun MD ,&nbsp;Sally L. Baxter MD, MSc ,&nbsp;Charlotte Gore MD ,&nbsp;Glenn Yiu MD, PhD","doi":"10.1016/j.oret.2025.03.003","DOIUrl":"10.1016/j.oret.2025.03.003","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 814-817"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143616664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymptomatic Vitreous Cyst Features Captured by Ultra-widefield Swept-Source OCT.","authors":"Hao Wu, Xiaoqing Chen, Dan Liang","doi":"10.1016/j.oret.2025.06.010","DOIUrl":"https://doi.org/10.1016/j.oret.2025.06.010","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-VEGF Use for Conditions without US Food and Drug Administration Approval","authors":"Ravi Parikh MD, MPH ,&nbsp;Elias H. Kahan MD ,&nbsp;Casey Zhang MD ,&nbsp;Rhiya Mittal MD ,&nbsp;Arjun Watane MD ,&nbsp;Flora C. Lum MD ,&nbsp;Scott M. Friedman MD","doi":"10.1016/j.oret.2025.03.014","DOIUrl":"10.1016/j.oret.2025.03.014","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 817-819"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity","authors":"Thomas W. Hejkal MD, PhD ,&nbsp;Shruti Sinha MBBS, MS ,&nbsp;Pukhraj Rishi MBBS, MS ,&nbsp;Samiksha F. Jain MD ,&nbsp;Paul J. Rychwalski MD","doi":"10.1016/j.oret.2025.02.009","DOIUrl":"10.1016/j.oret.2025.02.009","url":null,"abstract":"<div><h3>Purpose</h3><div>We reviewed outcomes using intravitreal bevacizumab 0.03 mg to treat retinopathy of prematurity (ROP) after switching to this dose in November 2018.</div></div><div><h3>Design</h3><div>Multicenter, retrospective, nonrandomized, nonmasked, consecutive case series.</div></div><div><h3>Subjects and Controls</h3><div>This study included 62 premature infants (123 eyes) diagnosed with type 1 ROP who were treated with low-dose bevacizumab (0.03 mg). A historical control group of infants who had received standard-dose bevacizumab (0.625 mg) was included for comparison.</div></div><div><h3>Methods</h3><div>Results from 62 patients (123 eyes) treated between November 2018 and September 2023 with low-dose intravitreal bevacizumab, 0.03 mg in 0.03 ml, by 4 treating physicians were reviewed.</div></div><div><h3>Main Outcome Measures</h3><div>Primary outcome measures were percentage of eyes having initial regression of ROP and percentage of eyes that received subsequent laser treatment. Secondary outcomes were time between bevacizumab and subsequent laser treatment, number of laser spots, and percentage with recurrence of ROP.</div></div><div><h3>Results</h3><div>All eyes had initial regression of ROP. Of the 123 eyes, 42 (34%) received laser treatment at some point after bevacizumab: 34 (28%) for persistent avascular retina (PAR) and 8 (7%) for reactivation of ROP. The average time between bevacizumab and laser was 16 ± 6 weeks for PAR and 13 ± 5.8 weeks for recurrent ROP. The mean number of laser spots per eye was 496 ± 247 for PAR and 905 ± 915 for recurrent ROP (<em>P</em> = 0.028). No eyes developed stage 4 or stage 5 ROP.</div></div><div><h3>Conclusions</h3><div>Based on historical comparisons, a 0.03-mg dose of intravitreal bevacizumab was as effective as a 0.625-mg dose for treatment of ROP. These data provide additional evidence from clinical practice to support the use of a 0.03-mg dose of bevacizumab for treatment of ROP.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosures may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 807-811"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Metastasis Secondary to Lung Cancer Treated with Local Photodynamic Therapy and Systemic Nivolumab","authors":"Mathieu Carriere MD, FRCSC,&nbsp;Kelsey A. Roelofs MD, FRCSC,&nbsp;Parampal S. Grewal MD, FRCSC","doi":"10.1016/j.oret.2024.12.012","DOIUrl":"10.1016/j.oret.2024.12.012","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Page e80"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haller’s and Sattler’s Layer Dysplasia—Possible Subtype of Choroidal Dysplasia?","authors":"Zhenlong Ran MD ,&nbsp;Jiayue Wang MD ,&nbsp;Dongyan Pan MD","doi":"10.1016/j.oret.2024.12.019","DOIUrl":"10.1016/j.oret.2024.12.019","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Page e81"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Risk Retinoblastoma Based on International Classification Systems","authors":"Deepthi E. Kurian MD ,&nbsp;Swathi Kaliki MD ,&nbsp;Carol L. Shields MD","doi":"10.1016/j.oret.2025.01.020","DOIUrl":"10.1016/j.oret.2025.01.020","url":null,"abstract":"<div><h3>Purpose</h3><div>To determine the predictive value of International Intraocular Retinoblastoma Classification schemes and the American Joint Committee on Cancer (AJCC) classification for histopathological high-risk features (HRFs).</div></div><div><h3>Design</h3><div>Multicentric international collaborative retrospective case series.</div></div><div><h3>Subjects</h3><div>One thousand three hundred and sixty-two patients with retinoblastoma from 16 centers and 11 countries.</div></div><div><h3>Intervention</h3><div>Primary enucleation; adjuvant therapy in patients with HRF.</div></div><div><h3>Main Outcome Measures</h3><div>High-risk retinoblastoma defined as 1 or more HRF (anterior segment involvement, massive choroidal invasion, minor choroidal infiltration with prelaminar optic nerve invasion, retrolaminar or resected optic nerve cut end involvement, scleral or microscopic extrascleral infiltration); metastasis-free survival (MFS).</div></div><div><h3>Results</h3><div>Of the 1362 patients, 751 (55.1%) had HRF. According to the International Classification of Retinoblastoma (ICRB) (Philadelphia vs. Los Angeles [LA]) versus Children’s Oncology Group (COG) classification schemes, the positive predictive value (PPV) of group D eyes for HRF was 42.0% versus 35.1% versus 43.2%, respectively, and that for group E eyes was 58.5% versus 59.0% versus 59.5%, respectively. Comparing group D versus group E eyes, there was higher mean number of HRF (standard deviation, range) among group E eyes using the ICRB Philadelphia (0.7 [0.9, 0.0–6.0] vs. 1.3 [1.7, 0.0–9.0], <em>P</em> &lt; 0.001), ICRB LA (0.6 [0.8, 0.0–6.0] vs. 1.3 [1.7, 0.0–9.0], <em>P</em> &lt; 0.001) and COG (0.8 [1.2, 0.0–7.0] vs. 1.3 [1.6, 0.0–8.0], <em>P</em> &lt; 0.001) classifications. The PPV for HRF was above 55% for AJCC clinical tumor (cT) group cT3a with increments through cT3e to 72.3%. An agreement between ICRB Philadelphia versus ICRB LA, ICRB LA versus COG, and ICRB Philadelphia versus COG was 0.9, 0.8, and 0.8, respectively (<em>P</em> &lt; 0.001). Metastasis-free survival rates and overall survival rates were also comparable between all intraocular retinoblastoma classification schemes but better stratified within the AJCC scheme.</div></div><div><h3>Conclusions</h3><div>All intraocular retinoblastoma classification schemes predict HRF and MFS equally. Group E includes a wide spectrum equivalent to the AJCC group cT3. Uniform grouping with subcategorization of group E might improve risk stratification. We propose that everyone across the retinoblastoma world henceforth adopts the AJCC classification for all reporting and publishing.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 8","pages":"Pages 787-797"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}